Assignee
TYK MEDICINES INC
CN·3 granted patents·9 pending applications·0 citations·filing 2018–2023
Top patents by PatentIndex Score
12 records- 0155US2025129086A1Compound for degrading egfr protein and use thereofTYK MEDICINES INC·Filed 2022·Application pending·0 cites
- 0254US2026078114A1Compound used as inhibitor of cdk4 kinase and use thereofTYK MEDICINES INC·Filed 2023·Application pending·0 cites
- 0351US10882845B2Crystal form of deuterated AZD9291, preparation method therefor, and use thereofTYK MEDICINES INC·Filed 2018·Granted Jan 5, 2021·0 cites·9 claims
- 0450US2025154105A1Polycyclic compound and use thereofTYK MEDICINES INC·Filed 2022·Application pending·0 cites
- 0549US12435089B23-oxadiazolyl substituted pyrazolo[1,5,a]pyrimidines for ROS1, NTRK, and ALK mediated diseasesTYK MEDICINES INC·Filed 2021·Granted Oct 7, 2025·0 cites·11 claims
- 0649US2024190887A1Compound used as shp2 inhibitor and use thereofTYK MEDICINES INC·Filed 2022·Application pending·0 cites
- 0749US2024025908A1Compound used as kinase inhibitor and use thereofTYK MEDICINES INC·Filed 2021·Application pending·0 cites
- 0845US12545681B2Compound used as RET kinase inhibitor and application thereofTYK MEDICINES INC·Filed 2021·Granted Feb 10, 2026·0 cites·13 claims
- 0944US2023095530A1Compound used as ret kinase inhibitor and application thereofTYK MEDICINES INC·Filed 2020·Application pending·0 cites
- 1042US2023026840A1Compound used as egfr kinase inhibitor and use thereofTYK MEDICINES INC·Filed 2020·Application pending·0 cites
- 1141US2022233513A1Compound used as ret kinase inhibitor and application thereofTYK MEDICINES INC·Filed 2020·Application pending·0 cites
- 1238US2023295130A1Compound useful as cdk7 kinase inhibitor and use thereofTYK MEDICINES INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →